Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine.
暂无分享,去创建一个
Masahiro Fukuoka | Andrew Emili | Douglas S Lee | A. Emili | A. Gramolini | M. Fukuoka | Douglas S. Lee | Peter P. Liu | Peter P. Liu | M. Ouzounian | Anthony O Gramolini | Peter P Liu | Maral Ouzounian
[1] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[2] Ian Humphery-Smith,et al. A human proteome project with a beginning and an end , 2004, Proteomics.
[3] N. Le Meur,et al. Distinct molecular portraits of human failing hearts identified by dedicated cDNA microarrays , 2004, European journal of heart failure.
[4] E Fleck,et al. The construction of the World Wide Web‐accessible myocardial two‐dimensional gel electrophoresis protein database “HEART‐2DPAGE”: A practical approach , 1996, Electrophoresis.
[5] R. Irizarry,et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. , 2005, Physiological genomics.
[6] L. Lazzeroni,et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , 2006 .
[7] W. Koch,et al. Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.
[8] M. Lehmann,et al. The long QT syndrome family of cardiac ion channelopathies: A HuGE review* , 2006, Genetics in Medicine.
[9] J. V. Van Beeumen,et al. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia–reperfusion , 2005, Experimental physiology.
[10] D. Khatry,et al. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification , 2003, BMC Cancer.
[11] Martin Farrall,et al. Genetic susceptibility to coronary artery disease: from promise to progress , 2006, Nature Reviews Genetics.
[12] H. Calkins,et al. Arrhythmogenic right ventricular dysplasia/ cardiomyopathy , 2005, Current treatment options in cardiovascular medicine.
[13] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[14] M. Dunn,et al. Construction of HSC‐2DPAGE: A two‐dimensional gel electrophoresis database of heart proteins , 1997, Electrophoresis.
[15] G. MacGowan,et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. , 2004, Journal of the American College of Cardiology.
[16] S. Hanash. Disease proteomics : Proteomics , 2003 .
[17] Christopher J. Lee,et al. A genomic view of alternative splicing , 2002, Nature Genetics.
[18] C. Carlson,et al. Mapping complex disease loci in whole-genome association studies , 2004, Nature.
[19] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[20] K. Margulies,et al. Mixed Messages: Transcription Patterns in Failing and Recovering Human Myocardium , 2005, Circulation research.
[21] P. Charron,et al. The genetic bases of cardiomyopathies , 2006 .
[22] Raimond L Winslow,et al. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes. , 2004, Genomics.
[23] B. Jugdutt,et al. Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia‐reperfusion injury: Functional proteomics studies , 2004, Proteomics.
[24] Stefan Kääb,et al. Global gene expression in human myocardium—oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure , 2004, Journal of Molecular Medicine.
[25] D. K. Arrell,et al. Cardiovascular proteomics: evolution and potential. , 2001, Circulation research.
[26] J. Epstein,et al. Detection of Cardiac Allograft Rejection and Response to Immunosuppressive Therapy With Peripheral Blood Gene Expression , 2004, Circulation.
[27] Xinqiang Han,et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. , 2004, Physiological genomics.
[28] C. Lane,et al. Mass spectrometry-based proteomics in the life sciences , 2005, Cellular and Molecular Life Sciences CMLS.
[29] Joshua M Hare,et al. Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. , 2005, Trends in cardiovascular medicine.
[30] M. Pirmohamed,et al. The future prospects of pharmacogenetics in oral anticoagulation therapy. , 2006, British journal of clinical pharmacology.
[31] E. Winzeler,et al. Genomics, gene expression and DNA arrays , 2000, Nature.
[32] J. V. Van Eyk,et al. A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two‐dimensional gel electrophoresis , 2005, Proteomics.
[33] Paul D Allen,et al. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. , 2002, The American journal of pathology.
[34] H. Kitano. Systems Biology: A Brief Overview , 2002, Science.
[35] Michael J Dunn,et al. Use of proteomics to discover novel markers of cardiac allograft rejection. , 2004, Journal of proteome research.
[36] George C Tseng,et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. , 2002, Physiological genomics.
[37] D. K. Arrell,et al. Proteomic Analysis of Pharmacological Preconditioning: Novel Protein Targets Converge to Mitochondrial Metabolism Pathways , 2006, Circulation research.
[38] R. Roberts. Mechanisms of Disease: genetic mechanisms of atrial fibrillation , 2006, Nature Clinical Practice Cardiovascular Medicine.
[40] G. Dorn,et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.
[41] L. Miller,et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. , 2003, Physiological genomics.
[42] E. Lakatta,et al. Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] Norbert Wiener,et al. Cybernetics: Control and Communication in the Animal and the Machine. , 1949 .
[44] Leena Peltonen,et al. Genetics of familial combined hyperlipidemia , 2006, Current opinion in lipidology.
[45] Manuel Hidalgo,et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. , 2003, Cancer research.
[46] Melanie Y. White,et al. Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems , 2005, Proteomics.
[47] J. Hopfield,et al. From molecular to modular cell biology , 1999, Nature.
[48] J. Listgarten,et al. Statistical and Computational Methods for Comparative Proteomic Profiling Using Liquid Chromatography-Tandem Mass Spectrometry , 2005, Molecular & Cellular Proteomics.
[49] Peipei Ping,et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. , 2006, Journal of the American College of Cardiology.
[50] L. Emens. Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer , 2005, American journal of therapeutics.
[51] J. V. Van Eyk,et al. Effective removal of albumin from serum , 2005, Proteomics.
[52] E. Petricoin,et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] R. Aebersold,et al. Mass spectrometry-based proteomics , 2003, Nature.
[54] M. Tyers,et al. From genomics to proteomics , 2003, Nature.
[55] Mark A Sussman,et al. Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy. , 2005, American journal of physiology. Heart and circulatory physiology.
[56] E. Müller,et al. High‐performance human myocardial two‐dimensional electrophoresis database: Edition 1996 , 1996, Electrophoresis.
[57] P. Ping,et al. Mapping the Murine Cardiac 26S Proteasome Complexes , 2006, Circulation research.
[58] J. Seidman,et al. A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.
[59] R. Tyndale,et al. Genetic Influences on Smoking: A Brief Review , 2005, Therapeutic drug monitoring.
[60] F. Collins,et al. A vision for the future of genomics research , 2003, Nature.
[61] A. Barabasi,et al. Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.
[62] S. Cook,et al. DNA Microarrays : Implications for Cardiovascular Medicine , 2002 .
[63] D. Levy,et al. Association of parental heart failure with risk of heart failure in offspring. , 2006, The New England journal of medicine.